カルナバイオサイエンスの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2020/08/12 | 1,345 | 1,398 | 1,336 | 1,358 | +23 | +1.7% | 104,500 |
2020/08/11 | 1,315 | 1,341 | 1,305 | 1,335 | +27 | +2.1% | 87,200 |
2020/08/07 | 1,313 | 1,317 | 1,292 | 1,308 | -3 | -0.2% | 61,000 |
2020/08/06 | 1,383 | 1,383 | 1,311 | 1,311 | -68 | -4.9% | 113,900 |
2020/08/05 | 1,357 | 1,384 | 1,355 | 1,379 | +22 | +1.6% | 53,800 |
2020/08/04 | 1,343 | 1,365 | 1,339 | 1,357 | +22 | +1.6% | 60,700 |
2020/08/03 | 1,285 | 1,339 | 1,280 | 1,335 | +34 | +2.6% | 56,100 |
2020/07/31 | 1,335 | 1,363 | 1,301 | 1,301 | -39 | -2.9% | 93,900 |
2020/07/30 | 1,338 | 1,351 | 1,317 | 1,340 | +2 | +0.1% | 47,000 |
2020/07/29 | 1,371 | 1,375 | 1,331 | 1,338 | -37 | -2.7% | 66,400 |
2020/07/28 | 1,362 | 1,403 | 1,362 | 1,375 | -10 | -0.7% | 64,600 |
2020/07/27 | 1,388 | 1,396 | 1,361 | 1,385 | -4 | -0.3% | 51,300 |
2020/07/22 | 1,365 | 1,402 | 1,365 | 1,389 | -9 | -0.6% | 58,000 |
2020/07/21 | 1,356 | 1,403 | 1,355 | 1,398 | +45 | +3.3% | 63,600 |
2020/07/20 | 1,350 | 1,371 | 1,335 | 1,353 | +3 | +0.2% | 49,500 |
2020/07/17 | 1,379 | 1,380 | 1,315 | 1,350 | -21 | -1.5% | 133,200 |
2020/07/16 | 1,391 | 1,405 | 1,370 | 1,371 | -33 | -2.4% | 54,600 |
2020/07/15 | 1,400 | 1,424 | 1,371 | 1,404 | +17 | +1.2% | 77,400 |
2020/07/14 | 1,412 | 1,423 | 1,362 | 1,387 | -22 | -1.6% | 148,100 |
2020/07/13 | 1,400 | 1,415 | 1,354 | 1,409 | +3 | +0.2% | 185,500 |
2020/07/10 | 1,414 | 1,424 | 1,382 | 1,406 | -29 | -2% | 149,300 |
2020/07/09 | 1,472 | 1,475 | 1,422 | 1,435 | -46 | -3.1% | 85,000 |
2020/07/08 | 1,450 | 1,513 | 1,440 | 1,481 | +30 | +2.1% | 92,200 |
2020/07/07 | 1,490 | 1,490 | 1,419 | 1,451 | -20 | -1.4% | 119,800 |
2020/07/06 | 1,429 | 1,478 | 1,421 | 1,471 | +19 | +1.3% | 73,000 |
2020/07/03 | 1,420 | 1,453 | 1,401 | 1,452 | +73 | +5.3% | 149,100 |
2020/07/02 | 1,480 | 1,491 | 1,360 | 1,379 | -116 | -7.8% | 342,000 |
2020/07/01 | 1,527 | 1,533 | 1,485 | 1,495 | -45 | -2.9% | 148,300 |
2020/06/30 | 1,597 | 1,608 | 1,506 | 1,540 | +23 | +1.5% | 195,200 |
2020/06/29 | 1,570 | 1,585 | 1,511 | 1,517 | -90 | -5.6% | 175,600 |
2020/06/26 | 1,690 | 1,690 | 1,592 | 1,607 | -43 | -2.6% | 233,000 |
2020/06/25 | 1,635 | 1,679 | 1,623 | 1,650 | -16 | -1% | 126,900 |
2020/06/24 | 1,633 | 1,681 | 1,633 | 1,666 | +31 | +1.9% | 116,100 |
2020/06/23 | 1,695 | 1,700 | 1,635 | 1,635 | -60 | -3.5% | 214,600 |
2020/06/22 | 1,665 | 1,735 | 1,640 | 1,695 | +29 | +1.7% | 200,700 |
2020/06/19 | 1,625 | 1,683 | 1,600 | 1,666 | +61 | +3.8% | 159,500 |
2020/06/18 | 1,672 | 1,672 | 1,587 | 1,605 | -63 | -3.8% | 234,700 |
2020/06/17 | 1,692 | 1,704 | 1,625 | 1,668 | -17 | -1% | 191,300 |
2020/06/16 | 1,620 | 1,699 | 1,600 | 1,685 | +175 | +11.6% | 261,200 |
2020/06/15 | 1,692 | 1,692 | 1,500 | 1,510 | -169 | -10.1% | 444,600 |
2020/06/12 | 1,605 | 1,707 | 1,590 | 1,679 | -46 | -2.7% | 284,700 |
2020/06/11 | 1,799 | 1,835 | 1,701 | 1,725 | -79 | -4.4% | 323,600 |
2020/06/10 | 1,784 | 1,820 | 1,757 | 1,804 | +9 | +0.5% | 216,800 |
2020/06/09 | 1,736 | 1,813 | 1,702 | 1,795 | +81 | +4.7% | 384,200 |
2020/06/08 | 1,649 | 1,740 | 1,629 | 1,714 | +77 | +4.7% | 369,800 |
2020/06/05 | 1,587 | 1,643 | 1,573 | 1,637 | +27 | +1.7% | 161,800 |
2020/06/04 | 1,634 | 1,652 | 1,568 | 1,610 | -16 | -1% | 304,400 |
2020/06/03 | 1,647 | 1,679 | 1,605 | 1,626 | -21 | -1.3% | 223,000 |
2020/06/02 | 1,630 | 1,652 | 1,602 | 1,647 | +31 | +1.9% | 156,500 |
2020/06/01 | 1,614 | 1,631 | 1,581 | 1,616 | +16 | +1% | 157,400 |
1051~
1100
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「カルナバイオ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
カルナバイオ | 31,000円 | -43.1% | - | 0.00% | - | 1.84倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
ノイルイミューン | 17,300円 | -97.8% | - | 0.00% | - | 1.50倍 |
|
独自技術用いたCAR-T細胞免疫療法で抗がん剤を複数開発中。中外製薬とライセンス契約 |
日ケミファ | 151,100円 | +2.5% | - | 3.31% | 90.86倍 | 0.29倍 |
|
中堅後発薬メーカー。長期収載品の主力は痛風薬ウラリット。新薬開発、検査薬事業を中期強化 |
VIS | 89,000円 | +87.8% | +265.7% | 0.00% | 53.45倍 | 2.45倍 |
|
mRNA標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
クリングル | 84,500円 | +240.0% | - | 0.00% | - | 2.75倍 |
|
細胞の増殖、保護、修復などの機能があるHGFタンパク質を用いて、難治性疾患治療薬を開発 |
市場注目の銘柄
チャート関連のコラム